AMAN SOLANKI

Experience

• 

  New vaccine house

  Feb 2022 - Mar 2022

  Retail Sales Manager
• 

  CHOITHRAM HOSPITAL AND RESEARCH CENTRE

  Mar 2022 - Jul 2022

  Hospital Pharmacist
• 

  Glenmark Pharmaceuticals

  Aug 2022 - Jun 2023

  here I'm handling a leading brand of ZESTA division(A division of Glenmark)🔹SACU-VSacubitril+ValsartanSacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class II, III, or IV.🔹RemozenRemogliflozin which belongs to the group of medicines called Anti-diabetic agents. It is used to treat type 2 diabetes mellitus. It helps control the high blood sugar levels seen in diabetes. This reduces the chances of serious complications of diabetes and also helps prevent heart disease.🔹Remozen-V Remogliflozin+ vildagliptinRemozen-V Tablet is a combination of two medicines used in the treatment of type 2 diabetes mellitus. It is approved for use in adults aged 18 years and older to improve glycemic control. It is generally used when other diabetes medicines do not provide adequate glycemic control. Show less I started my journey in shwas division glenmark pharmaceuticalsour focus on chronic Respiratory diseaseslike COPD ASHTMA I'm handling the portfolio of brand like✓VILOR-F✓AIRZ✓AIRZ-FB✓DIGIHALER FB✓AIRTEC FB✓NINDANIB✓GLEMONT FDue to merger and consolidation of shwas-3 division into Shwas 1 &2 i internally transferred to Zoltan division of Glenmark pharmaceuticalshere I'm handling legacy Brand of cardiac segment✓ Telma 20/40/80 mg( telma takes charge by 18 )✓Telma-H (DCP STUDY)✓PAXIBA (Apixaban 2.5/5mg)✓Telma D✓Ruvaxon✓Telma-AZ✓Azeldipafter that I transferred to ZESTA Division of Glenmarkhere I'm handling portfolio of Anti heart failure & Diabetic segmentfollowing drugs are ✓SACU-V (Sacubitril &Valsartan 50/100/200 mg)✓Remozen (Remogliflozin)✓Remozen MV✓Remozen V✓Remozen M✓Telma MCT✓Telma-Beta (AHA &ACC CIRCULATION✓Irban 5 mg[Ivabradine] ✓Irban beta Show less

  • Executive trainee

    Jan 2023 - Jun 2023

  • Executive Trainee

    Aug 2022 - Jan 2023
• 

  Bayer

  Jun 2023 - Aug 2024

  Therapy Business Manager

  One CKM PORTFOLIOKERENDIA (FINERENONE)VERQUVO (VERICIGUAT)XARELTO(REVOROXABAN)GLUCOBAY (ACARBOSE)🔸KERENDIA (FINERENONE🔸Kerendia (finerenone) is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. MR overactivation is thought to contribute to fibrosis and inflammation. Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors🔸VERQUVO (VERICIGUAT)🔸VERQUVO directly stimulates sGC, independently of and synergistically with NO, to produce more cGMP leading to smooth muscle relaxation and vasodilation which may improve cardiac function.Vericiguat is a medication used to manage and treat heart failure with reduced ejection fraction (HFrEF). It is useful for chronic worsening heart failure and recently decompensated heart failure, high-risk heart failure with reduced ejection fraction, especially for patients who had been rehospitalized or are on intravenous diuretic therapy, or patients requiring urgent treatment for heart failure. Vericiguat does not prolong survival but prevents rehospitalization. This activity outlines the indications, mechanism of action, dose, and mode of administration by the interprofessional team, adverse effects, contraindications, monitoring parameters, and several trials to support the evidence of the drug's usefulness in HFrEF. It also highlights the role of an interprofessional team in managing patients with heart failure using vericiguat. Show less

• 

  Novartis

  Aug 2024 - now

  Territory business executive